Advertisement
News
Advertisement

Miraculins Issued Chinese Patent on PreVu(R) Skin Cholesterol Technology

Thu, 06/14/2012 - 3:45am
The Associated Press

(http://www.miraculins.com/ )

Miraculins Inc. (TSX VENTURE: MOM), a medical diagnostic company

focused on acquiring, developing and commercializing diagnostic tests

and risk assessment technologies for unmet clinical needs, announces

today that it has been issued a patent by the State Intellectual

Property Office of the People's Republic of China that covers use of a

tape stripping device for skin sampling. The issued patent covers

elements of the PreVu@ Non-Invasive Skin Cholesterol Lab Processed

(LP) Test, specifically relating to the LP collection device, which is

used to collect the skin samples which are then sent to a central lab

for processing and measuring the skin cholesterol values.

"We have global plans for our PreVu Skin Cholesterol technology,"

stated Christopher J. Moreau, President and Chief Executive Officer of

Miraculins Inc. "This simple to use laboratory based version of the

PreVu technology could prove to be very attractive in certain key

emerging markets. Miraculins is very enthusiastic about PreVu's

potential risk assessment role in the fight against cardiovascular

disease, the world's leading cause of death and disability."

The PreVu LP Test non-invasively measures the amount of cholesterol

that has been deposited in skin tissues by painlessly and rapidly

collecting skin cells from the palm of the hand using a proprietary

medical adhesive collection device, which would then be sealed and

sent to a laboratory for processing. The sample collection process is

easily self-performed, takes fifteen seconds to conduct and does not

require fasting. The PreVu LP Test is Miraculins' second format of its

innovative PreVu Non-Invasive Cholesterol Test technology and is being

developed as part of a broader commercialization strategy. In Canada,

the final development and commercialization of the LP Test is

partnered with Gamma-Dynacare Medical Laboratories, one of Canada's

largest and most respected medical laboratories.

Miraculins recently announced the Notice of Allowance for a U.S.

patent providing coverage on its PreVu Point of Care (POC) Test

format, and the launch of a new English Canadian website for PreVu

(www.prevu.com(http://www.prevu.com)).

About The PreVu@ Non-Invasive Skin Cholesterol Test

Skin cholesterol is the cholesterol that has been deposited and

diffused into tissue, as opposed to freely circulating in the

bloodstream, and has been shown in clinical trials to be strongly

associated with significant coronary artery disease (CAD) as measured

by treadmill stress testing, coronary angiography, coronary calcium,

carotid artery thickening and carotid artery plaque. The PreVu POC

Test is completely painless, non-invasive, involves no blood draw or

needles, requires no overnight fasting and involves no handling of

potentially hazardous biomaterials. It has been developed to provide

new and additive information about CAD risk that is independent of

traditional risk factors, such as blood cholesterol, to help

physicians more effectively assess their patients' risk. The test is

conducted on the palm of the hand in less than 5 minutes with results

being immediately available.

About Miraculins Inc.

Miraculins is a medical diagnostic company focused on acquiring,

developing and commercializing non-invasive tests for unmet clinical

needs. A significant number of promising diagnostic opportunities

remain un-commercialized because of the sizable gap between the

discovery stage, when research institutions are typically involved,

and the commercialization stage, when the larger commercial

enterprises become interested. Miraculins has direct experience in

bridging this gap. The Company's PreVu technology is a revolutionary

new coronary artery disease risk assessment technology that measures

cholesterol levels in a patient's skin non-invasively, painlessly and

without the need for fasting. Miraculins is also advancing a suite of

biomarkers to aid in the early detection of the devastating disease of

pregnancy known as preeclampsia. The Company's preeclampsia program is

partnered with Alere, Inc. (NYSE: ALR) (formerly known as Inverness

Medical Innovations), one of the world's largest diagnostic companies.

For more information on Miraculins please visit

www.miraculins.com(http://www.miraculins.com).

Caution Regarding Forward-Looking Information

Certain statements contained in this press release constitute

forward-looking information within the meaning of applicable Canadian

provincial securities legislation (collectively, "forward-looking

statements"). These forward-looking statements relate to, among other

things, our objectives, goals, targets, strategies, intentions, plans,

beliefs, estimates and outlook, including, without limitation, our

anticipated future operating results, and can, in some cases, be

identified by the use of words such as "believe," "anticipate,"

"expect," "intend," "plan," "will," "may" and other similar

expressions. In addition, any statements that refer to expectations,

projections or other characterizations of future events or

circumstances are forward-looking statements.

These statements reflect management's current beliefs and are based on

information currently available to management. Certain material

factors or assumptions are applied in making forward-looking

statements, and actual results may differ materially from those

expressed or implied in such statements. Important factors that could

cause actual results to differ materially from these expectations

include, among other things: Miraculins' early stage of development,

lack of product revenues and history of operating losses,

uncertainties related to clinical trials and product development,

rapid technological change, uncertainties related to forecasts,

competition, potential product liability, additional financing

requirements and access to capital, unproven markets, supply of raw

materials, income tax matters, management of growth, partnerships for

development and commercialization of technology, effects of insurers'

willingness to pay for products, system failures, dependence on key

personnel, foreign currency risk, risks related to regulatory matters

and risks related to intellectual property and other risks detailed

from time to time in Miraculins' filings with Canadian securities

regulatory authorities, as well as Miraculins' ability to anticipate

and manage the risks associated with the foregoing. Additional

information about these factors and about the material factors or

assumptions underlying such forward-looking statements may be found in

the body of this news release. Miraculins cautions that the foregoing

list of important factors that may affect future results is not

exhaustive. When relying on Miraculins' forward-looking statements to

make decisions with respect to Miraculins investors and others should

carefully consider the foregoing factors and other uncertainties and

potential events.

These risks and uncertainties should be considered carefully and

prospective investors should not place undue reliance on the

forward-looking statements. Although the forward-looking statements

contained in this press release are based upon what management

believes to be reasonable assumptions, Miraculins cannot provide

assurance that actual results will be consistent with these

forward-looking statements. Miraculins undertakes no obligation to

update or revise any forward-looking statement.

PreVu@ is a registered trademark of Miraculins Inc. All Rights

Reserved. 2012.

Neither TSX Venture Exchange nor its Regulation Services Provider (as

that term is defined in the policies of the TSX Venture Exchange)

accepts responsibility for the adequacy or accuracy of this release.

Advertisement

Share this Story

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading